- Home
- LOT vs HCM Comparison
LOT vs HCM Comparison
Compare LOT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOT
- HCM
- Stock Information
- Founded
- LOT 1948
- HCM 2000
- Country
- LOT China
- HCM Hong Kong
- Employees
- LOT N/A
- HCM N/A
- Industry
- LOT
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- LOT
- HCM Health Care
- Exchange
- LOT NYSE
- HCM Nasdaq
- Market Cap
- LOT 2.0B
- HCM 2.3B
- IPO Year
- LOT N/A
- HCM N/A
- Fundamental
- Price
- LOT $2.57
- HCM $16.11
- Analyst Decision
- LOT
- HCM Hold
- Analyst Count
- LOT 0
- HCM 1
- Target Price
- LOT N/A
- HCM $19.00
- AVG Volume (30 Days)
- LOT 145.0K
- HCM 73.5K
- Earning Date
- LOT 04-07-2025
- HCM 03-19-2025
- Dividend Yield
- LOT N/A
- HCM N/A
- EPS Growth
- LOT N/A
- HCM N/A
- EPS
- LOT N/A
- HCM N/A
- Revenue
- LOT $1,013,890,000.00
- HCM $610,806,000.00
- Revenue This Year
- LOT $41.67
- HCM N/A
- Revenue Next Year
- LOT $65.29
- HCM $15.89
- P/E Ratio
- LOT N/A
- HCM N/A
- Revenue Growth
- LOT 213.08
- HCM N/A
- 52 Week Low
- LOT $2.21
- HCM $12.84
- 52 Week High
- LOT $17.99
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- LOT 42.12
- HCM 68.69
- Support Level
- LOT $2.21
- HCM $13.58
- Resistance Level
- LOT $3.57
- HCM $13.96
- Average True Range (ATR)
- LOT 0.27
- HCM 0.31
- MACD
- LOT 0.04
- HCM 0.34
- Stochastic Oscillator
- LOT 26.47
- HCM 89.84
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.